Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company is starting four new pivotal trials this year.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
